UCB reformulating Parkinson's patch to eliminate crystals

Biopharma company UCB will reformulate its Parkinson's disease and restless leg syndrome drug Neupro before making it available on the U.S. market, per recommendation of the FDA. The regulator's decision answers an NDA supplement submitted by the Belgian drugmaker in June 2009, which proposed new refrigerated storage conditions to alleviate crystallization on the transdermal patches. The FDA agreed that improved storage helped alleviate the problem, but reformulation provided "definitive resolution." Item

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.